Congratulations to Nallathamby lab’s @JohannaOlesk on successfully defending her Masters thesis for Bioengineering in Summer 2023. Her thesis was titled ” Phage-Mimicking Nanoparticles Conjugated with Antimicrobial Peptides and Polymers as an Alternative to Antibiotic Treatment.” She passed with unanimous consent. We wish her all the best in her future undertakings. #WomenInSTEM#notredame#GoIrish Special mention to all the undergraduate researchers and the technicians who contributed immensely to getting this thesis across the finish line, as Johanna dealt with her first pregnancy.
« Translational Science to Impact Public Health was our Goal at Techconnect 2023
1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL) »
Jul 07
Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis
Categories:
antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, Graduate Student, multidrug resistance, Thesis defense, Uncategorized
by Prakash
This post has no tag
Recent Posts
- Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL) August 30, 2024
- Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa August 21, 2024
- Precision Health and Diagnostics Session Chair at Techconnect World Innovation Conference (2024) June 19, 2024
- MTEC Annual meeting in Baltimore MD (May 24, 2024) May 24, 2024
- Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 May 7, 2024
Archives
Categories
NIH Funding Opportunities
- Notice of Early Expiration of the Tobacco Regulatory Science K Notice of Funding Opportunity Announcements (NOFOs): RFA-OD-22-023, RFA-OD-22-024, RFA-OD-22-025, and RFA-OD-22-026 September 20, 2024Notice NOT-OD-24-172 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Quantum Sensing in Biomedical Applications (SBIR/STTR) September 20, 2024Notice NOT-EY-24-014 from the NIH Guide for Grants and Contracts
- Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional) September 20, 2024Funding Opportunity PAR-24-298 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) will support pilot, feasibility or exploratory research in 5 priority areas in substance use epidemiology and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden […]
- Notice of NIH Participation in the National Science Foundation Solicitation NSF 24-603: Biomedical Research Initiative for Next-Gen BioTechnologies - SynBio Control (BRING SynBio) September 20, 2024Notice NOT-EB-24-012 from the NIH Guide for Grants and Contracts
- Notice of Participation of the NIAAA in RFA-HD-25-003 "Pediatric HIV/AIDS Cohort Study (PHACS) (U19 Clinical Trial Not Allowed)" September 20, 2024Notice NOT-AA-24-010 from the NIH Guide for Grants and Contracts
- Notice of Change: NINDS Participation in PAR-24-131/PAR-24-133 "Small Business Transition Grant for New Entrepreneurs" (R43/R44 Clinical Trial Not Allowed)/(R41/R42 Clinical Trial Not Allowed) September 20, 2024Notice NOT-NS-24-134 from the NIH Guide for Grants and Contracts
- Notice of Question and Answer "Office Hours" with NIH Staff for the Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) Funding Opportunities RFA-DA-25-037, RFA-DA-25-038 September 19, 2024Notice NOT-DA-24-042 from the NIH Guide for Grants and Contracts
- Notice of Participation of the NIAAA in NOSI: Analysis of Existing Linked Datasets to Understand the Relationship between Housing Program Participation and Risk for Chronic Diseases and Other Conditions (R01-Clinical Trial Not Allowed). September 19, 2024Notice NOT-AA-24-009 from the NIH Guide for Grants and Contracts
- HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) September 18, 2024Funding Opportunity RFA-NS-25-023 from the NIH Guide for Grants and Contracts. This funding opportunity is part of a suite of NOFOs within the NIH HEAL Initiative to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal is to encourage initial translational efforts that will support a drug discovery program and […]
- Notice of Participation of the National Cancer Institute (NCI) in RFA-NS-24-041, "NIH HEAL Initiative: Coordinated Approaches to Pain Care in Health Care Systems (UG3/UH3 - Clinical Trial Optional). September 18, 2024Notice NOT-CA-24-108 from the NIH Guide for Grants and Contracts
Recent Comments